• Denisse Castro-Eguiluz, Salim A Barquet-Muñoz, Ana C Arteaga-Gómez, Rosa A Salcedo Hernández, Amelia Rodríguez-Trejo, Dolores Gallardo-Rincón, Juan A Serrano-Olvera, and Carlos Aranda-Flores.
• Consejo Nacional de Ciencia y Tecnología (CONACYT)-Department of Clinical Research, Instituto Nacional de Cancerología (INCan), Mexico City, Mexico.
• Rev Invest Clin. 2020 Jan 1; 72 (4): 239-249.

AbstractHuman papillomavirus (HPV) has been associated with the development of precancerous lesions of the cervix and cervical cancer (CC). Prophylactic HPV vaccination induces the development of a specific memory immune response that facilitates HPV elimination once the natural infection occurs. At present, in addition to the prophylactic vaccine, therapeutic vaccines are being developed and researched with the aim of inducing an immune response that allows the elimination of HPV-infected cells. The purpose of this study is to describe the current evidence on the use of therapeutic vaccines and their effect on cervical precancerous lesions, to establish recommendations on their clinical use. So far, the studies that have generated results have described a marginal beneficial effect of the prophylactic vaccine in the management of infection and pre-invasive lesions. Based on the evidence, continuing research on the efficacy and safety of therapeutic vaccines for the treatment of cervical intraepithelial lesions is recommended. The use of the HPV prophylactic vaccine as treatment for pre-existing lesions is not advised, but it is recommended to prevent new lesions.Copyright: © 2020 Permanyer.

15 keywords...

hide…